Yuhang Deng

Yuhang Deng

Auto-generated profile, based on publicly available information

Yuhang Deng

National Center for Clinical Laboratories, Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YDYuhang Deng
Yuhang Deng
CZChao Zhang
Chao Zhang
JWJing Wang
Jing Wang
JZJie Zeng
Jie Zeng
JZJiangtao Zhang
Jiangtao Zhang
CZChuanbao Zhang
Chuanbao Zhang
Yuhang Deng, M.D., Chao Zhang, M.D., Jing Wang, M.M., Jie Zeng, M.M., Jiangtao Zhang, M.M., Tianjiao Zhang, M.D., Haijian Zhao, M.M., Weiyan Zhou, M.D., and Chuanbao Zhang, M.D.. Ann Lab Med 2023;43:345-54. https://doi.org/10.3343/alm.2023.43.4.345

1 July 2022 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
WZWeiyan Zhou
Weiyan Zhou
M.M.D.
M.D.
YDYuhang Deng
Yuhang Deng
HZHaijian Zhao
Haijian Zhao
CZChuanbao Zhang
Chuanbao Zhang
Weiyan Zhou , M.D., Yuhang Deng , M.D., Haijian Zhao , M.D., and Chuanbao Zhang , M.D.. Ann Lab Med 2022;42:428-37. https://doi.org/10.3343/alm.2022.42.4.428

1 September 2022 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YDYuhang Deng
Yuhang Deng
QLQingxiang Liu
Qingxiang Liu
ZLZhenni Liu
Zhenni Liu
HZHaijian Zhao
Haijian Zhao
WZWeiyan Zhou
Weiyan Zhou
CZChuanbao Zhang
Chuanbao Zhang
Yuhang Deng, M.D., Qingxiang Liu, M.S., Zhenni Liu, M.D., Haijian Zhao, M.D., Weiyan Zhou, M.D., and Chuanbao Zhang, M.D.. Ann Lab Med 2022;42:575-84. https://doi.org/10.3343/alm.2022.42.5.575

29 March 2024 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
WZWeiyan Zhou
Weiyan Zhou
YDYuhang Deng
Yuhang Deng
WMWenjun Ma
Wenjun Ma
HZHaijian Zhao
Haijian Zhao
KWKai juan Wang
Kai juan Wang
CZChuanbao Zhang
Chuanbao Zhang
Objectives: Accurate measurements of renin and aldosterone levels play an important role in primary aldosteronism screening, which is of great importance in the management and categorization of hypertension. The objective of this study is to investigate the current status of plasma renin and aldosterone measurements in China, which is achieved by analyzing the results of 526 clinical laboratories nationwide for three pooled fresh plasma samples derived from more than 2,000 patients. Methods: Renin and aldosterone in three pooled plasma samples were measured four times in 526 laboratories employing various measurement systems. The inter- and intra-laboratory %CV were calculated and compared. To determine the source of the substantial inter-laboratory %CV, laboratories were categorized according to the measurement systems they are using, and both the inter- and intra-measurement-system %CV were calculated and compared. Results: Regarding renin, the majority of laboratories use four primary commercial immunoassays. However, for aldosterone, in addition to commercial immunoassays, laboratory-developed liquid chromatography-tandem mass spectrometry (LC-MS) methods are also used by laboratories. The median values of intra-laboratory %CVs, intra-measurement-system %CVs, inter-laboratory %CVs, and inter-measurement systems %CVs varied between 1.6 and 2.6 %, 4.6 and 14.9 %, 8.3 and 25.7 %, and 10.0 and 34.4 % for renin, respectively. For aldosterone, these values ranged from 1.4 to 2.2 %, 2.5–14.7 %, 9.9–31.0 %, and 10.0–35.5 %, respectively. Conclusions: The precision within laboratories and measurement systems for plasma renin and aldosterone measurements is satisfactory. However, the comparability between laboratories using different measurement systems remains lacking, indicating the long way to achieve standardization and harmonization for these two analytes.

1 May 2025 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
WZWeiyan Zhou
Weiyan Zhou
JZJie Zeng
Jie Zeng
LZLinhui Zhang
Linhui Zhang
JZJiangtao Zhang
Jiangtao Zhang
YDYuhang Deng
Yuhang Deng
JMJie Ma
Jie Ma
Objectives: Therapeutic drug monitoring (TDM) is critical for optimizing antipsychotic therapy, yet inter-laboratory comparability in China remains poor. Unstandardized practices risk suboptimal dosing and adverse effects, highlighting the need for standardization. This study evaluated TDM practices for six antipsychotics (olanzapine, clozapine, risperidone, quetiapine, aripiprazole, and paliperidone), focusing on inter-laboratory variability, quality control material suitability, and measurement system differences. Methods: Four processed serum samples (two frozen, two lyophilized) containing the six antipsychotic drugs were distributed to over 100 laboratories. The analyses utilized LC-MS/MS, chemiluminescence immunoassays, and HPLC. Sample homogeneity, stability, matrix effects, and method precision, and accuracy were assessed systematically. Results: Significant inter-laboratory variability occurred for six antipsychotics. Only quetiapine met the external quality assessment (EQA) requirements, with inter-laboratory coefficients of variation (CVs) ranging from 12.08 to 15.23 %. Others, especially olanzapine (CVs: 43.48–45.30 %), had poor precision (CVs>15 %). The study revealed that commercial in vitro diagnostic kits generally provided more consistent results compared to laboratory-developed tests. However, even with commercial kits, some drugs, such as aripiprazole, still showed substantial deviations. Lyophilized samples surpassed frozen ones in stability and EQA suitability, which exhibited comparable matrix effects across most assay systems. Conclusions: Urgent standardization of Chinese TDM practices is needed, including harmonized systems and traceable calibrators. While commercial kits enhance result consistency, further efforts are required to harmonize performance across manufacturers. Lyophilized materials are optimal for EQA due to their stability and ease of transport. These findings offer actionable insights to improve the quality and comparability of antipsychotic TDM in clinical practice.

3 April 2023 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
YDYuhang Deng
Yuhang Deng
CZChao Zhang
Chao Zhang
BLBingqiong Li
Bingqiong Li
JWJing Wang
Jing Wang
JZJie Zeng
Jie Zeng
CZChuanbao Zhang
Chuanbao Zhang
Objectives: To find suitable external quality assessment (EQA) materials for serum C-peptide, we evaluated the commutability of five types of processed materials. Methods: Seventy-four individual serum samples and 12 processed samples including three EQA samples currently in use, frozen human serum pools (FHSP), and three other kinds of processed samples were prepared by dissolving WHO International Standard Reagent for C-peptide (WHO ISR 13/146) in three different matrixes: 0.05 % bovine serum albumin, fetal bovine serum and human serum pools. Samples were analyzed using the isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method and six widely used immunoassays. The commutabilities of processed materials were assessed according to the difference in bias approach recommended by the IFCC. And the short- and long-term stability of FHSP samples at different temperatures were also evaluated. Results: Out of the five kinds of processed materials, FHSP samples were commutable on most assays. In contrast, the EQA materials currently in use were only commutable on a few immunoassays. Additionally, processed materials derived from WHO ISR 13/146 were found to be un-commutable on over half of immunoassays. The FHSP samples could be stably stored at 4 and −20 °C for at least 16 days, and at −80 °C for at least 1 year, but at room temperature only for 12 h. Conclusions: With clarified commutability and stability information, the human serum pool samples along with the developed ID-LC-MS/MS method could be used in the EQA program to promote the comparability among laboratories for C-peptide measurement in China.